Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCL) is an essential electrolyte used to prevent or treat hypokalemia. It is available in oral and intravenous (IV) formulations. ## Primary Indications * Treatment and prevention of hypokalemia. ## Adult Dosing * **Oral:** * **Prevention:** 20 mEq (10 mmol) per day, divided into 1-2 doses. * **Treatment:** 40-100 mEq (20-50 mmol) per day, divided into 2-4 doses. Maximum daily dose typically 200 mEq (100 mmol) over several days. * **Sustained-release formulations:** Usually 8-20 mEq (4-10 mmol) once or twice daily. * **Intravenous (IV):** * **Mild to moderate hypokalemia (serum K+ 2.5-3.5 mEq/L):** Infuse at a rate not to exceed 10 mEq/hour. Total daily dose typically 40-80 mEq (20-40 mmol), not to exceed 200 mEq (100 mmol) in 24 hours. * **Severe or symptomatic hypokalemia or when oral administration is not feasible (serum K+ <2.5 mEq/L):** May require more rapid infusion (e.g., up to 20-40 mEq/hour in critical care settings with continuous cardiac monitoring). **Extreme caution is required.** * **Maximum concentration:** Typically 40 mEq/L (20 mmol/L) for peripheral IV infusion and 80 mEq/L (40 mmol/L) for central IV infusion. Higher concentrations may be used in emergent situations under strict monitoring. ## Pediatric Dosing * **Oral:** Recommended daily intake varies by age. For treatment of hypokalemia, doses are individualized based on serum potassium levels and clinical status, typically ranging from 2-4 mEq/kg/day, divided into 2-4 doses. Maximum daily dose generally does not exceed 100 mEq/m²/day. * **Intravenous (IV):** Dosing is highly individualized based on age, weight, severity of hypokalemia, and cardiac status. * **General maintenance:** 2-3 mEq/kg/day. * **Treatment of hypokalemia:** 0.5-1 mEq/kg per dose may be given over 1-3 hours. Total daily doses can range from 20-40 mEq/kg/day (maximum typically 100 mEq/day). * **Infusion rates and concentrations:** Similar principles to adults apply, with slower rates and lower concentrations preferred for peripheral administration. **Continuous cardiac monitoring is crucial for IV potassium administration, especially in pediatric patients.** ## Dose Adjustments * **Renal impairment:** Dose must be reduced. Potassium is renally excreted; impaired renal function increases the risk of hyperkalemia. Use with extreme caution or avoid if severe renal impairment. * **Adrenal insufficiency:** May require lower doses. ## Contraindications * Hyperkalemia (serum K+ > 5 mEq/L). * Conditions that predispose to hyperkalemia (e.g., severe renal failure, untreated Addison's disease, anuria, oliguria, certain gastrointestinal conditions like untreated addisonian crisis). * Certain formulations (e.g., sustained-release oral products) may be contraindicated in patients with delayed gastric emptying or esophageal compression. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal discomfort, flatulence. * **Serious:** Hyperkalemia (which can lead to cardiac arrhythmias, muscle weakness, paresthesia, paralysis, and cardiac arrest). * **IV specific:** Phlebitis, pain at injection site, vascular damage (especially with rapid infusion or high concentrations). ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia. * **ACE inhibitors (e.g., lisinopril, enalapril), Angiotensin II Receptor Blockers (ARBs) (e.g., losartan, valsartan):** Increased risk of hyperkalemia. * **NSAIDs (e.g., ibuprofen, naproxen):** May reduce potassium excretion, increasing risk of hyperkalemia. * **Heparin:** May inhibit aldosterone production, increasing risk of hyperkalemia. * **Digoxin:** Hyperkalemia can potentiate digoxin toxicity; hypokalemia can increase digoxin toxicity. ## Monitoring * **Serum potassium levels:** Frequently, especially during IV administration and with dose changes. * **Renal function (BUN, creatinine):** To assess risk of accumulation. * **ECG:** Especially with IV potassium administration or suspected hyperkalemia. * **Signs and symptoms of hypokalemia or hyperkalemia.** ## Clinical Pearls * Oral potassium chloride should be taken with meals or a full glass of water to minimize gastrointestinal irritation. * Slow-release oral formulations may reduce gastrointestinal upset but can be associated with esophageal irritation or ulceration if not taken with adequate fluid. * IV potassium must be administered with extreme caution due to the risk of fatal hyperkalemia and cardiac arrest. **Never administer IV potassium push.** * In patients with severe hypokalemia or those requiring rapid correction, central venous access is preferred for IV potassium administration to allow for faster infusion rates and better monitoring. * Dosing for specific electrolyte imbalances (e.g., post-operative, diuretic-induced) may vary and should be guided by local protocols and patient-specific factors. *** *This information is intended for healthcare professionals. It is essential to consult the most current official prescribing information and relevant clinical guidelines for complete details and to ensure patient safety. Dosing and management decisions should always be individualized based on patient-specific factors.*